Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Express Scripts
Moodys
Argus Health
Covington
Federal Trade Commission
Deloitte
US Army
Teva

Generated: January 23, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 208325

« Back to Dashboard

NDA 208325 describes PARSABIV, which is a drug marketed by Kai Pharms Inc and is included in one NDA. It is available from one supplier. There are five patents protecting this drug. Additional details are available on the PARSABIV profile page.

The generic ingredient in PARSABIV is etelcalcetide. One supplier is listed for this compound. Additional details are available on the etelcalcetide profile page.
Summary for 208325
Tradename:PARSABIV
Applicant:Kai Pharms Inc
Ingredient:etelcalcetide
Patents:5
Generic Entry Opportunity Date for 208325
Generic Entry Date for 208325*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 208325
Suppliers and Packaging for NDA: 208325
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
PARSABIV etelcalcetide SOLUTION;INTRAVENOUS 208325 NDA Amgen Inc 55513-740 55513-740-10 10 VIAL, SINGLE-DOSE in 1 CARTON (55513-740-10) > .5 mL in 1 VIAL, SINGLE-DOSE (55513-740-01)
PARSABIV etelcalcetide SOLUTION;INTRAVENOUS 208325 NDA Amgen Inc 55513-741 55513-741-10 10 VIAL, SINGLE-DOSE in 1 CARTON (55513-741-10) > 1 mL in 1 VIAL, SINGLE-DOSE (55513-741-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAVENOUSStrength2.5MG/0.5ML (2.5MG/0.5ML)
Approval Date:Feb 7, 2017TE:RLD:Yes
Regulatory Exclusivity Expiration:Feb 7, 2022
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:➤ Try a Free TrialPatent Expiration:Jul 29, 2030Product Flag?YSubstance Flag?YDelist Request?
Patent:➤ Try a Free TrialPatent Expiration:Jul 29, 2030Product Flag?YSubstance Flag?YDelist Request?
Patented Use:A METHOD OF TREATING SECONDARY HYPERPARATHYROIDISM (SHPT)

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
US Department of Justice
Fuji
AstraZeneca
Cipla
Cantor Fitzgerald
Harvard Business School
Accenture
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.